Childhood eczema — clinically known as atopic dermatitis — affects roughly 10-15% of American children, making it one of the most common chronic skin conditions in pediatrics. It usually starts in the first year of life, follows a relapsing-remitting course through childhood, and resolves or improves substantially in many children by adolescence. Eczema is also the leading edge of the “atopic march,” the developmental sequence in which infants with severe early eczema have higher risk of food allergy, asthma, and allergic rhinitis later. Treatment has improved considerably in the last decade with new topical and biologic options that go well beyond the older steroid-and-moisturizer model.
What Eczema Is
Atopic dermatitis is a chronic, inflammatory skin disease driven by a combination of skin barrier dysfunction (often from filaggrin gene mutations), immune dysregulation toward type 2 inflammation, and environmental triggers. The result is dry, itchy, inflamed skin that flares and remits, often along characteristic age-specific patterns: cheeks and scalp in infants, flexural creases (elbows, knees, neck) in older children, and similar flexural plus hand involvement in adolescents and adults.
The hallmark symptom is itch — sometimes intense enough to disrupt sleep and concentration. Scratching damages the skin further, creating an itch-scratch cycle that worsens inflammation and risks bacterial superinfection, especially with Staphylococcus aureus. Per the National Eczema Association and Cleveland Clinic, severity ranges from mild occasional dryness to severe, debilitating disease covering most of the body.
Causes and Triggers
The underlying drivers are genetic. Children with a parent or sibling with eczema, asthma, or allergic rhinitis are at significantly higher risk. Common triggers that worsen flares include: dry climate and low humidity, hot water bathing, harsh soaps and detergents, fragrances in skin care and laundry products, wool and synthetic fabrics, sweating and overheating, stress, and viral upper respiratory infections. Environmental allergens like dust mites, pet dander, and pollen can drive flares in some children.
Food allergy plays a smaller role than parents often assume. About one-third of children with moderate-to-severe eczema have at least one IgE-mediated food allergy, but identifying and removing food triggers rarely cures eczema, and elimination diets done without allergist supervision often cause more harm than benefit.
Diagnosis
Eczema is diagnosed clinically based on history and the appearance and distribution of skin findings. Pediatricians and dermatologists use the Hanifin-Rajka criteria or simpler practical features: pruritus (itch), typical age-appropriate distribution, chronic relapsing course, and personal or family history of atopy. Biopsy is rarely needed.
Allergy testing is reserved for cases with suspected specific IgE-mediated triggers — typically severe, refractory eczema in infants where food allergy is suspected, or older children with environmental triggers. Routine broad food allergy panels are not recommended and lead to many false positives.
Treatment: The Modern Stepwise Approach
The 2023 AAD-AAP guidelines for atopic dermatitis emphasize a stepwise approach. Step one is daily moisturization with thick fragrance-free emollients — petrolatum-based ointments and creams generally outperform lotions. Apply liberally at least twice daily, especially within 3 minutes after bathing (“soak and seal”). Daily lukewarm baths with mild fragrance-free cleansers, followed immediately by moisturizer, are generally preferred over infrequent bathing for most patients.
Step two adds topical anti-inflammatories during flares. Low-potency topical corticosteroids (hydrocortisone 1-2.5%) for face and skin folds, mid-potency (triamcinolone, mometasone) for body. Used appropriately and short-term, topical steroids are safe and effective. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) and the newer non-steroid options crisaborole, ruxolitinib cream, and roflumilast cream can be used for sensitive areas or as steroid-sparing maintenance.
Step three is for moderate-to-severe disease that does not respond to topicals. Systemic options now include dupilumab (Dupixent), approved down to 6 months of age, which is an injectable biologic targeting the IL-4/IL-13 pathway. JAK inhibitors (upadacitinib, abrocitinib) are options for older children and adolescents. Phototherapy, methotrexate, cyclosporine, and azathioprine remain options in selected cases.
Bleach Baths and Infection Control
Children with eczema are colonized with Staphylococcus aureus at much higher rates than the general population. Frequent superinfection with weeping, crusted, or honey-colored lesions warrants topical or oral antibiotics. Dilute bleach baths (about 1/4 to 1/2 cup of regular household bleach in a full bathtub of water, twice weekly, soaked for 5-10 minutes) reduce bacterial colonization and flare frequency in moderate-to-severe disease per AAD guidance, though benefit is modest.
Eczema herpeticum — disseminated herpes simplex infection on eczematous skin — is a dermatologic emergency. It presents as punched-out vesicles that can become widespread and is treated with systemic acyclovir or valacyclovir.
The Atopic March
Severe early eczema is associated with substantially increased risk of subsequent food allergy, asthma, and allergic rhinitis. The 2017 NIAID peanut allergy prevention guidelines specifically recommend introducing peanut by 4-6 months in high-risk infants — those with severe eczema, egg allergy, or both — to substantially reduce peanut allergy risk. Aggressive eczema control in infancy may modify the atopic march, though evidence on long-term prevention of asthma is mixed.
When to See a Pediatrician or Dermatologist
Routine eczema is usually managed by pediatricians. Refer to a pediatric dermatologist for: eczema not controlled with mid-potency topical steroids and consistent moisturization, suspected allergic contact dermatitis, frequent skin infections, eczema affecting sleep or quality of life, suspected eczema herpeticum, and consideration of systemic therapy or biologics like dupilumab. Allergists are appropriate when food allergy is strongly suspected or when environmental triggers are unclear.
When to seek emergency care: Call 911 or go to the emergency room if your child develops widespread punched-out vesicular lesions (suspected eczema herpeticum), high fever with rapidly spreading red painful skin (suspected severe bacterial infection), facial swelling with breathing difficulty (anaphylaxis), or signs of sepsis such as lethargy, mottled skin, or extremely fast breathing. Most eczema flares are not emergencies, but secondary infections occasionally are.
Daily Practical Care
Practical day-to-day care that pediatric dermatologists recommend: lukewarm short baths, fragrance-free non-soap cleansers, immediate moisturization with thick ointment after bathing, soft cotton clothing, fragrance-free laundry detergent, double-rinsing laundry, keeping nails trimmed short, cool sleeping environment, and identifying personal triggers. Hard water has been associated with eczema in some studies, though dedicated water softeners have not consistently shown benefit in trials.
Frequently Asked Questions
Will my child outgrow eczema?
Many children improve substantially by adolescence. Roughly half outgrow it largely or completely, and another portion experience milder, more localized disease into adulthood. Children with severe early eczema, family history of atopy, and early food allergy are more likely to have persistent disease.
Is eczema contagious?
No. Eczema itself is not contagious. Bacterial superinfection (impetigo on eczema) and eczema herpeticum can be contagious, so cover infected lesions until treated.
Should I avoid bathing my child to keep their skin from drying out?
The current evidence supports daily lukewarm short baths with mild cleansers followed immediately by thick moisturizer. The “soak and seal” technique hydrates the skin barrier better than infrequent bathing.
Is dupilumab safe for young children?
Dupilumab is FDA-approved down to 6 months of age for moderate-to-severe atopic dermatitis. It targets IL-4 and IL-13 pathways and has a strong safety profile in clinical trials, with conjunctivitis being the most common side effect. It is generally reserved for moderate-to-severe disease not controlled with topical therapy.
The Bottom Line on Childhood Eczema
Childhood eczema is a chronic, manageable condition with well-established treatments and increasingly effective options for severe disease. Daily moisturization, gentle bathing, and appropriate topical anti-inflammatories during flares control most cases. Severe disease deserves dermatology referral early — both for skin control and to manage the atopic march toward asthma and food allergies. Regular well-child visits are a good place to track flare frequency, growth (eczema severity sometimes affects sleep and growth), and overall pediatric care within the larger context of chronic childhood conditions.